Eli Lilly, Novo waging price wars as obesity drug market heats up in China
Source: SeekingAlpha
2025-12-30 07:43:40 ET
More on Eli Lilly, Novo Nordisk
- Novo Nordisk: The Real Comeback Starts Now With The Wegovy Pill
- Eli Lilly: Mr. Market Finally Woke Up, But I'm Not Out Yet (Rating Downgrade)
- Eli Lilly: Short-Term Upside Exhausted (Rating Downgrade)
- CMS unveils payment model to boost GLP-1 access for Medicare Part D, Medicaid
- GLP-1 weight loss meds lead to changes in consumer food demand - study
Read the full article on Seeking Alpha
For further details see:
Eli Lilly, Novo waging price wars as obesity drug market heats up in China
Innovent Biologics Inc ADR
NASDAQ: IVBIY
IVBIY Trading
-4.51% G/L:
$40 Last:
1,006 Volume:
$41.89 Open:
IVBIY Latest News
January 26, 2026 07:00:00 pm
Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma
January 08, 2026 07:00:00 pm
Innovent's Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration
